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Thrombocytosis in primary lung cancer
Aekaterini A. Kotsori, M.M. Vaslamatzis, C.G. Alexopoulos
A B S T R A C T
BACKGROUND The prevalence of thrombocytosis in lung cancer has been variably re-
ported from 13% to 60%. The vast majority of published data derive from retrospec-
tive studies and therefore the estimation of the real prevalence is difficult.
PATIENTS AND METHODS We prospectively enumerated platelets in the peripheral 
blood of 317 consecutive, untreated lung cancer patients. Thrombocytosis was defined 
as a pletelet count >400.000/mm3. Tumours were histopathologically classified ac-
cording to the WHO classification and staging was performed according the 2002 
version ISS for NSCLC and to the VALSG two stage system for SCLC.
RESULTS Thrombocytosis was present in 64 (20.2%) patients and it was unrelated to 
gender and extent of disease but it was age related: 29/91 (31.8%) in patients ≤50 yrs 
versus 35/226 (15%) in patients >50yrs old (p=0.001). The distribution of thrombo-
cytosis in the two major histological types was 54/165 (32.7%) for NSCLC and 10/152 
(6.6%) for SCLC (p<0.001). Thrombocytosis did not differ (p=0.13) between NSCLC 
subtypes: adenocarcinomas (37/95, 39%), squamous cell carcinomas (11/48, 23%) and 
large cell carcinomas (6 22, 27%). Time to progression (TTP) did not differ (p=0.2) 
between thrombocytemic and non-thrombocytemic patients. On the contrary, 142/253 
(56%) non-thrombocytemic patients responded to chemotherapy versus 21 of 64 
(32.8%) thrombocytemic patients (p=0.001).
CONCLUSIONS Thrombocytosis is rather uncommon in untreated patients with SCLC 
while it is present in about one third of patients with NSCLC and it is unrelated to 
clinical stage or gender but related to age. In SCLC, it is unrelated to stage, gender or 
age. The presence of thrombocytosis in NSCLC and SCLC does not affect TTP. It is 
inversely related to response to chemotherapy but only in NSCLC.
I N T R O D U C T I O N
Thrombocytosis, defined as a platelet count of more than 400.000/mm3 is a well 
known paraneoplastic manifestation in a variety of malignant neoplasms, including 
lung cancer1-5. Nevertheless, the reported prevalence of thrombocytosis varies widely 
between different series, ranging from as low as 13%6 to as high as 60%7. Likewise, 
there is considerable disagreement, in the literature, about the correlation of throm-
bocytosis with the various histological types of lung carcinoma2,3,8,9. More importantly, 
the vast majority of published, so far, data derive from retrospective studies making 
conclusions about the real prevalence of thrombocytosis difficult.
We, therefore, thought that a prospective estimation of platelets number in untreated 
patients with lung carcinoma would provide interesting information on the topic.
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S T U D y  A I M
The primary endpoint of the present study was to estimate, 
in a prospective manner, the prevalence of thrombocytosis in 
patients with primary lung carcinoma before the administra-
tion of any treatment for their tumour.
Secondary endpoints were: a) the comparison of throm-
bocytosis between the various histological types and sub-
types, b) the evaluation of the potential prognostic value of 
thrombocytosis in terms of response to treatment and c) the 
evaluation of the potential effect of thrombocytosis on the 
time to progression (TTP).
To this effect, we determined, in a prospective way, platelets 
count in the peripheral blood of all lung cancer patients con-
secutively admitted in the Department of Medical Oncology 
between 1999 and 2005 if they fulfilled the study’s eligibility 
criteria.
P A T I E N T S  A N D  M E T H O D S
E L I G I B I L I T y  A N D  E x C L U S I O N  C R I T E R I A
In order to be included in the study patients had to fulfill 
all the inclusion and exclusion criteria shown in table 1.
L A B O R A T O R y  I N v E S T I G A T I O N S
The following investigations were performed:
History and detailed clinical examination
Haemoglobin, white blood count, differential count, platelets
urea, creatinine, liver function tests, electrolytes
Chest X-ray and CT scan of the thorax
bronchoscopy and biopsy of any abnormal findings
CT scan of the abdomen
CT scan of the brain
bone scintigraphy
S T A G I N G
Patients with NSCLC were staged according to the cur-
rent 2002 version of the International Staging System (ISS)1. 
Patients with SCLC were staged according to the two stage 
system introduced by the Veterans’ Affairs Lung Study Group 
(VALSG) into Limited Disease (LD) and Extensive Disease 
(ED)2.
M E T H O D S
Peripheral venous blood for platelets enumeration was 
drawn before any specific therapy i.e. surgery, irradiation or 
chemotherapy was given. Platelet counts were analysed using 
an electronic particle counting device on blood using EDTA 
as anticoagulant. Thrombocytosis was defined as a pletelet 
count >400.000/mm3
Histopathology was assessed using morphological and im-
munohistochemical criteria. Tumours were histopathologically 
classified according to the WHO classification3.
E vA L U A T I O N  O f  R E S P O N S E  T O  T R E A T M E N T
WHO criteria were used to evaluate response to treatment. 
More specifically:
Complete Response (CR) was defined as complete disap-
pearance of all tumour lesions for a duration of at least three 
weeks
Partial Response (PR) was defined as decrease of >50% 
in the sum of the product of cross-sectional diameters of well 
outlined lesions or >50% decrease of poorly outlined lesions 
for at least three weeks, in the absence of progressive disease 
elsewhere or occurrence of new lesions elsewhere.
Progressive Disease (PD) was defined as >25% increase 
in the product of cross-sectional diameters of one or more 
outlined lesions or the occurrence of new lesions irrespectively 
of response elsewhere
S T A T I S T I C A L  C O N S I D E R A T I O N S
Comparative analysis of the prevalence of thrombocytosis 
between the different groups was performed using Pearson 
chi-square test. The same test was used for comparative 
analysis of response rates between thrombocytemic and non-
thrombocytemic patients.
Time to progression was separately estimated for throm-
bocytemic and non-thrombocytemic patients, using the Ka-
plan-Meier method and comparison of the two curves was 
performed by the logrank test.
All statistical analyses were carried out in SPSS v 13.0
R E S U L T S
between 1999 and 2005, 317 consecutive patients with 
TABLE 1. Eligibility criteria
Inclusion criteria
• Histologically or cytologically confirmed carcinoma of the lung
• No previous therapy for their tumour of any kind
• Stages I-IV
• Availability for follow up
• Informed consent
Exclusion criteria
• Suggestive or proven bone marrow involvement
• Known or suspicious myeloproliferative or myelodysplastic syn-
drome
• Prior splenectomy for any reason
• Idiopathic thrombocytopenic purpura
• Cirrhosis
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primary lung cancer were included in the study. Their demo-
graphic, clinical and laboratory characteristics are shown in 
table 2. There were 165 (52%) NSCLC and 152 (48%) SCLC 
patients. The distribution of the different histological subtypes 
among NSCLC histology were: 95 (58%) adenocarcinomas, 
48 (29%) squamous cell carcinomas and 22 (13%) large cell 
carcinomas. Expressed as a percentage of the whole group of 
317 lung cancer patients, adenocarcinomas represented 30%, 
squamous cell carcinomas 15% and large cell carcinomas 7% 
of cases, respectively. Of 317 patients, 274 (86%) were males 
and 43 (14%) were females. The corresponding figures for 
NSCLC were 143 (87%) and 22 (13%), respectively and for 
SCLC 131 (86%) and 21 (14%), respectively. Median age of 
the whole group was 61 years with a range from 29 to 82. One 
hundred and twenty five (39%) patients had localized disease 
while the corresponding figures were 66 (40%) and 59 (39%) 
for NSCLC and SCLC, respectively. Table 3 summarizes our 
findings. Of the 317 patients, 64 (20.2%) had platelet count 
above 400.000/mm3. Separate analysis of our results accord-
ing to the two major histological types, demonstrated that 54 
of 165 (32.7%) patients with NSCLC were thrombocytemic 
compared with 10 of 152 (6.6%) patients with SCLC and this 
difference is highly significant (p<0.001). The distribution 
of stage among the 54 thrombocytemic NSCLC patients was 
as follows: one patient had stage IIA, 4 patients stage IIb, 7 
patients IIIA, 4 patients IIIb and 38 patients stage IV. In the 
whole group of 317 patients, analysis according to the disease 
extent, demonstrated that among 125 patients with localized 
disease, 21 (16.8%) had thrombocytosis compared with 43 of 
192 (22.4%) patients with metastatic disease (p=0.225). When 
these results were further analyzed according to the two major 
histologies (table 4), 16 of 66 (24.2%) patients with localized 
NSCLC were thrombocytemic compared with 5 of 59 (8.5%) 
patients with localized SCLC (p=0.019). The corresponding 
figures for metastatic disease were 38 of 99 (38.4%) patients 
with NSCLC compared with 5 of 93 (5.4%) patients with 
SCLC (p<0.001). Of the 274 male patients (table 3), 55 (20%) 
had thrombocytosis compared with 9 of 43 (20.9%) women 
(p=NS). The corresponding figures for NSCLC (table 4) were 
48 of 143 (33.6%) males versus 6 of 22 (27.3%) females (p=NS) 
and for SCLC, 7 of 131 (5.3%) males versus 3 of 21 (14.3%) 
females (p=NS). When the prevalence of thrombocytosis 
in males and females was compared between the two major 
histological types (table 5), it was found that 48 of 143 (33.6%) 
NSCLC male patients were thrombocytemic versus 7 of 131 
(5.3%) SCLC males (p=<0.001). The corresponding figures 
for females were 6 of 22 (27.3%) in NSCLC versus 3 of 21 
(14.3%) in SCLC (p=0.29). Analysis according to age (table 
3), demonstrated that 29 of 91 (31.8%) patients aged ≤50 years 
were thrombocytemic compared with 35 of 226 (15%) aged 
>50 years (p= 0.001). When aged related thrombocytosis was 
separately analyzed in the two major histopathological types 
(table 4), 24 of 52 (46.2%) NSCLC patients aged ≤50 years 
demonstrated thrombocytosis compared with 30 of 113 (26.5%) 
NSCLC patients aged >50 years (p=0.013). The correspond-
ing figures for SCLC were 5 of 39 (12.8%) patients aged ≤50 
TABLE 2. Patients Characteristics
NSCLC SCLC Total
Patients No (%) 165 (52) 152 (48) 317 (100)
Male (%)
Female (%)
143 (87)
22 (13)
131 (86)
21 (14)
274 (86)
43 (14)
Median age
(range)
61
(29-81)
61
(33-82)
61
(29-82)
Localised (%)
Metastatic (%)
66 (40)
99 (60)
59 (39)
93 (61)
125 (39)
192 (61)
Adenocarcinoma (%)
Squamous cell carcinoma (%)
Large cell carcinoma (%)
95 (58)
48 (29)
22 (13)
NA
NA
NA
TABLE 3. Results
Patients 
No
Thrombocytosis 
(%)
P value
All patients 317 64 (20)
Male
Female
274
43
55 (20)
9 (20.9)
P=NS
Age ≤50 years
Age >50 years
91
226
29 (31.8)
35 (15.5)
P=0.001
NSCLC
SCLC
165
152
54 (32.7)
10 (6.6)
p<0.001
Localised
Metastatic
125
192
21 (16.8)
43 (22.4)
P=NS
TABLE 4. Prevalence of thrombocytosis in NSCLC and 
SCLC patients according to demographic and clinical 
characteristics
 NSCLC SCLC
Male
Female
48/143 (33.6)
6/22 (27.3)
p=NS
7/131 (5.3)
3/21 (14.3)
p=NS
Age ≤50 years
Age >50 years
24/52 (46.2)
30/113 (26.5)
p=0.013
5/39 (12.8)
5/113 (4.4)
p=NS
Localised
Metastatic
16/66 (24.2)
38/99 (38.4)
p=NS
5/59 (8.5)
5/93 (5.4)
p=NS
Adenocarcinoma
Sqamous carcinoma 
Large cell carcinoma
37/95 (39)
11/48 (23)
6/22 (27)
p=NS
NA
NA
NA
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TABLE 5. Comparative prevalence of sex-related and age-
related thrombocytosis between the two major histological 
types of lung cancer
Parameter NSCLC SCLC P value
Male 48/143 (33.6%) 7/131 (5.3%) P <0.001
Female 6/22 (27.3%) 3/21 (14.3%) P = 0.29
Age ≤50 yrs 24/52 (46.2%) 5/39 (12.8%) P = 0.001
Age >50 yrs 30/113 (26.5%) 5/113 (4.4%) P =0.001
years versus 5 of 113 (4.4%) patients aged >50 years (p=NS). 
A comparison of age related thrombocytosis between the two 
major histological types (table 5) demonstrated that 24 of 52 
(46.2%) NSCLC patients aged ≤50 years were thrombocytemic 
versus 5 of 39 (12.8%) SCLC patients of similar age (p=0.001). 
The corresponding figures for patients >50 years were 30 of 
113 (26.5%) in NSCLC versus 5 of 113 (4.4%) in SCLC (P 
<0.001). The distribution of thrombocytosis in the various 
histological subtypes of NSCLC are shown in table 4. Of 95 
patients with adenocarcinoma 37 (39%) were thrombocytemic, 
of 48 patients with squamous cell carcinoma 11 (23%) were 
thrombocytemic and of 22 patients with large cell carcinomas 
6 (27%) were thrombocytemic. These figures were not sig-
nificantly different (p=0.13). In the whole group of patients, 
median time to progression (TTP) was 8.5 months (95% CI, 7 
– 9.9) for patients with platelets count ≤400.000/mm3 compared 
with 6 months (95% CI, 4.7 – 7.3) for patients with platelets 
count >400.000/mm3. The corresponding figures for the two 
major histological types were 5 months (95% CI, 3.6 – 6.4) and 
7 months (95% CI, 5.2 – 8.7) for NSCLC and 6 months (95% 
CI, 0 – 13) and 10 months (95% CI, 8 – 12) for SCLC. TTP 
curves of thrombocytemic and non-thrombocytemic patients 
are plotted in figure 1 for the whole group of patients and 
in figures 2 and 3 for NSCLC and SCLC, respectively. The 
logrank test demonstrated no significant difference in TTP 
for any comparison (p=0.2, p=0.3 and p=0.7, respectively) 
between thrombocytemic and non-thrombocytemic patients. 
We then proceeded to evaluate any possible correlation between 
platelets number and response to chemotherapy (table 6). The 
chemotherapeutic regimens used were platinum-based triplets 
for NSCLC and a combination of Vincristine and Doxorubicin 
day 1, Cyclophosphamide and Methotrexate day 2 and VP- 16 
days 1-5 q3W for SCLC. One hundred forty two of 253 (56%) 
non-thrombocytemic patients responded to chemotherapy 
versus 21 of 64 (32.8%) thrombocytemic patients (p=0.001). 
A separate analysis for the two major histological types dem-
onstrated that 49 of 111 (44%) NSCLC non-thrombocytemic 
patients responded to chemotherapy versus 15 of 54 (27.7%) 
thrombocytemic patients, a significant (p=0.043) difference. 
The corresponding figures for SCLC were 93 of 142 (65%) non-
thrombocytemic patients versus 6 of 10 (60%) thrombocytemic 
patients and this difference is not significant (p= 0.48).
N
on
-p
ro
gr
es
si
ng
 p
at
ie
nt
s 
%
D I S C U S S I O N
Although the association of thrombocytosis and lung can-
cer has been previously described4-10,12, its prevalence varies 
widely between different series, ranging from 13%9 to 60%10. 
A great deal of this variance is apparently due to the consider-
able disagreement of published studies about the correlation 
of thrombocytosis with the various histological types of lung 
fIGURE 1. Actuarial time to progression (TTP) curve for the 
whole group of patients.
fIGURE 2. Actuarial time to progression (TTP) curve for 
NSCLC patients.
≤ 400,000/mm3
> 400,000/mm3
≤ 400,000/mm3
> 400,000/mm3
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TABLE 6. Correlation between thrombocytosis and re-
sponse to chemotherapy
Responders/Nonresponders (%)
Nonthrombo- 
cytemic
Thrombocytemic P value
All patients 142/253 (56) 21/64 (32.8) P= 0.001
NSCLC 49/111 (44) 15/54 (27.7) P= 0.043
SCLC 93/142 (65) 6/10 (60) P= 0.48
carcinoma.5,6,11, 12 On the other hand, since the vast majority of 
published data derive from retrospective studies any conclusions 
about the real prevalence of thrombocytosis in primary lung 
cancer are debatable. From this point of view, we think that 
the findings of our prospective study, comprising a sizeable 
number of patients, provide useful information on the subject. 
Prior to discussing our findings a comment seems necessary 
explaining the unusual distribution of the two major histologi-
cal types in our patients population. The high representation 
of SCLC in our series is due to the referral pattern of patients 
to our department. Since our main source of referrals is the 
department of thoracic surgery, almost all SCLC patients, 
irrespectively of stage, are referred to our department for 
medical treatment in contrast to the majority of early stage 
NSCLC patients who are treated surgically.
We observed thrombocytosis in 20.2% of the whole group 
of patients studied, a prevalence closer to the lower end of 
published series7-9,12. The prevalence of thrombocytosis did 
not differ significantly between localized and extensive disease 
and this is at variance with the findings of Pedersen et al5. 
Likewise, no difference was found according to sex. On the 
contrary, thrombocytosis was significantly more frequent in 
patients younger than 50 years compared with patients 50 years 
and older. It is of interest that a correlation of thrombocytosis 
with age was observed only in the group of NSCLC patients. 
Significant correlation between thombocytosis and age has 
been previously reported by Aoe although there is no mention 
in his report of a possible interaction with histology8.
Comparison of the prevalence of thrombocytosis between 
the two major histological types of lung cancer demonstrated 
a highly significant difference, with thrombocytosis occur-
ring in almost one third of patients with NSCLC while only a 
small percentage of SCLC patients had platelets count above 
400.000/mm3. It is worth of notice that the difference remained 
significant when comparison between NSCLC and SCLC 
patients was performed according to age and the extent of 
the disease. As far as sex is concerned, the difference between 
NSCLC and SCLC remained significant only in male patients. 
To our knowledge, the aforementioned findings have not been 
previously reported.
No significant differences in prevalence of thrombocytosis 
were observed among the various histological subtypes of 
NSCLC and this observation is in agreement with the find-
ings of other studies.5,6,8 In order to discern any prognostic 
or predictive significance of thrombocytosis, we compared 
TTP and response rate between thrombocytemic and non-
thrombocytemic patients. We found that TTP was not affected 
by the presence of thrombocytosis either in the whole group 
of patients or in the two major histological types, separately. 
On the contrary, thrombocytosis was found to be inversely 
associated with response rate. In a separate analysis of the 
two major histological types, this negative association was 
restricted to NSCLC patients.
C O N C L U S I O N S
Thrombocytosis is rather uncommon in untreated patients 
with SCLC while is present in about one third of patients with 
NSCLC. In NSCLC, it is not related to clinical stage or gender 
but it is age related. In SCLC, thrombocytosis is unrelated to 
stage, gender or age. The presence of thrombocytosis does not 
affect TTP. However, in NSCLC, its presence seems to consti-
tute an unfavourable factor for response to chemotherapy.
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